Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2376 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Retreversine
CAS:<p>Retreversine serves as an inactive control counterpart to Reversine, a pioneering class of ATP-competitive Aurora kinase inhibitor.</p>Fórmula:C21H27N7OCor e Forma:SolidPeso molecular:393.49mTOR/HDAC-IN-1
CAS:mTOR/HDAC-IN-1, a dual inhibitor for mTOR & HDAC1 with IC50s 0.49 & 0.91 nM, potential anti-cancer agent.Fórmula:C23H23N11O3Cor e Forma:SolidPeso molecular:501.5M-1211
CAS:M 1121 is a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regression.Fórmula:C42H57FN6O6SCor e Forma:SolidPeso molecular:793.01INCB059872
CAS:<p>INCB059872: potent, oral, selective LSD1 inhibitor for myeloid leukemia research.</p>Fórmula:C23H34N2O3Cor e Forma:SolidPeso molecular:386.536MZP-55
CAS:MZP-55 is a selective BRD3/4 degrader based on PROTAC technology(Brd4BD2 with Kd of 8 nM)Fórmula:C57H70ClN7O10SPureza:98%Cor e Forma:SolidPeso molecular:1080.73XF056-132
CAS:XF056-132 is a potent WDR5 (WD40 repeat domain protein 5) PROTAC degrader [1] .Fórmula:C51H57F4N9O7SCor e Forma:SolidPeso molecular:1016.11(S,R,S)-AHPC-C5-COOH
CAS:E3 ligase ligand-linker '(S,R,S)-AHPC-C5-COOH' for PROTACs, VH032 inhibits VHL/HIF-1α with 185 nM Kd, may aid anemia and ischemic disease research.Fórmula:C29H42N4O5SPureza:98%Cor e Forma:SolidPeso molecular:558.73PROTAC BRD9-binding moiety 1
CAS:PROTAC BRD9-binding moiety 1 that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.Fórmula:C23H25N3O7S2Pureza:98%Cor e Forma:SolidPeso molecular:519.59PROTAC SMARCA2/4-degrader-27
CAS:PROTAC SMARCA2/4-degrader-27 (PROTAC 2) serves as a targeted degrader, utilizing PROTAC technology to degrade both SMARCA2 and SMARCA4.Fórmula:C49H58FN9O6SCor e Forma:SolidPeso molecular:920.117-Hydroxyneolamellarin A
CAS:7-Hydroxyneolamellarin A, from Dendrilla nigra, inhibits HIF-1α and VEGF in cancer research.Fórmula:C24H19NO5Cor e Forma:SolidPeso molecular:401.41TCIP3
CAS:<p>TCIP3 is a bivalent molecular glue (molecular glue) that can simultaneously bind to both p300/CBP and BCL6. It redirects p300 and CBP to activate programmed cell death genes, which are typically repressed by the oncogenic driver BCL6. TCIP3 is useful for studying diffuse large B-cell lymphoma (DLBCL) and is not toxic to untransformed tonsil lymphocytes or fibroblasts.</p>Fórmula:C58H71ClF2N16O7Cor e Forma:SolidPeso molecular:1177.74SIRT1/2/3-IN-1
CAS:<p>Potent SIRT1/2/3-IN-1 inhibits SIRT1/2/3 with IC50: 0.54, 0.25, 0.72 μM; used in cancer research.</p>Fórmula:C46H63N9O8S2Cor e Forma:SolidPeso molecular:934.18Axltide
CAS:Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Fórmula:C63H107N19O20S2Pureza:98%Cor e Forma:SolidPeso molecular:1514.77NF-κB/HIF-1α-IN-1
NF-κB/HIF-1α-IN-1 (compound 9c) effectively inhibits the NF-κB activation pathway and demonstrates selective antifibrotic activity. This compound exhibits no significant cytotoxicity in NCI tumor cell lines. In rat models, NF-κB/HIF-1α-IN-1 successfully ameliorates liver fibrosis, suppresses the expression levels of NF-κB and HIF-1α, and induces Nrf2.Fórmula:C24H27N7O4Cor e Forma:SolidPeso molecular:477.21245AURKA against 1
<p>Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.</p>Fórmula:C28H32FN9O2Cor e Forma:SolidPeso molecular:545.61MS2133
<p>MS2133 is a DOT1L PROTAC degrader. It facilitates the ubiquitination and degradation of DOT1L in THP-1 and MV4-11 cells, with DC50 values of 56 nM and 25 nM, respectively, and reduces H3K79 methylation. MS2133 also inhibits the growth of MLL-r leukemia cells, demonstrating anticancer activity.</p>Fórmula:C58H66ClF3N14O11S2Cor e Forma:SolidPeso molecular:1290.41175Neuropeptide DF2
CAS:Neuropeptide DF2 is an FMRFamide-related neuropeptide from crayfish.Fórmula:C44H67N15O10Pureza:98%Cor e Forma:SolidPeso molecular:966.1EZH2-IN-5
CAS:<p>EZH2-IN-5, potent EZH2 inhibitor; IC50: 1.52 nM (wild-type), 4.07 nM (Tyr641 mutant).</p>Fórmula:C26H37BrN4O2Cor e Forma:SolidPeso molecular:517.512Menin-KMT2A-IN-1
Menin–KMT2A-IN-1 (Compound 20) is an inhibitor of menin–KMT2A, binding to menin with an IC50 of 8 nM, and disrupting the interaction between menin and lysine methyltransferase 2A (KMT2A). It inhibits hERG channels with an IC50 of 65 μM and suppresses MV4-11 cells with an IC50 of 74 nM. Furthermore, Menin–KMT2A-IN-1 exhibits favorable pharmacokinetic properties in CD-1 mice, with an oral bioavailability of 74%.Fórmula:C28H35FN6O3Cor e Forma:SolidPeso molecular:522.61
